Johnson & Johnson Firms Things Up
By
Brian Orelli, Ph.D.
December 1, 2008
|
It looks like Johnson & Johnson (NYSE: JNJ) is taking a little of Warren Buffett's advice to buy when others are fearful. With the economy in the dumps, no one's interested in owning aesthetic medical product makers, but the health-care giant came swooping in today and bought Mentor (NYSE: MNT), a manufacturer of breast implants and body contouring equipment, for a little over $1 billion.
The price works out to $31 per share. While that's a 92% premium over Friday's close, Mentor had traded much higher than that less than a year ago. There's certainly plenty of blood in the streets of the aesthetic industry -- rival breast-implant maker Allergan (NYSE: AGN) is down more than 40% year to date.
Johnson & Johnson has something that many investors don't have: time and patience. The company can afford to wait for the economy to turn around. It's expecting to take a hit to earnings of $0.03 to $0.05 per share next year, but I imagine the purchase will begin to pay off in 2010. That's a lifetime for most investors.
Not only is Johnson & Johnson making a wise choice to spend its money now, it's also making good choices in where to spend the cash. The drug arena is also filled with beaten-down companies, but rival pharmaceutical companies have a lot of cash, too, which leads to companies still going for premiums -- witness King Pharmaceuticals' (NYSE: KG) purchase of Alpharma (NYSE: ALO), and Eli Lilly's (NYSE: LLY) pickup of ImClone Systems. Johnson & Johnson is making a good move sticking with expanding the medical device side of the business, and purchasing partners that no one else is likely to bid up, like Omrix Biopharmaceuticals (Nasdaq: OMRI).
With a yield above 3% and a highly diversified revenue stream in a fairly recession-proof industry, there's not much to complain about in Johnson & Johnson. And its latest acquisition sure does make it a looker.
Follow along with the Global Gains team as they travel to key business centers in China to uncover the very best investing opportunities! Sign up here to receive their FREE dispatches from the road.